Recent Study: Algeria Pharmaceuticals & Healthcare Report Q3 2014
The major developments this quarter were local drugmaker Saidal's two licensing manufacturing agreements with foreign drugmakers, and the Algerian College of Cardiologists' call for new hypertension medicines, which illustrates growing interest in the market and an increase in the opportunities on offer. Despite the country's large pharmaceutical market, of which patented medicines comprise 58% of the market value, we believe multinational interest in fixed capital investment will remain subdued due to the government's pro-generic policies and weak intellectual property law.
View full press release